Apr 19, 2022
John Glasspool is the CEO of Anthos Therapeutics, a clinical stage biopharmaceutical company focused on high-risk cardiovascular and metabolic diseases. Anthos is developing innovative therapies for treating thrombosis or more commonly known as clots that are caused by a stroke or heart attack. The current agents, while...
Apr 19, 2022
John Glasspool is the CEO of Anthos Therapeutics, a clinical stage biopharmaceutical company focused on high-risk cardiovascular and metabolic diseases. Anthos is developing innovative therapies for treating thrombosis or more commonly known as clots that are caused by a stroke or heart attack. The current agents, while...
Apr 18, 2022
Dr. Robert Foster is the CEO and Founder of Hepion Pharmaceutical which is developing Rencofilstat, a drug in the category of cyclophilin inhibition to target cyclophilins a specific type of enzyme that is present in all humans. These cyclophilins perform a number of functions and are responsible to some extent for the...
Apr 18, 2022
Dr. Robert Foster is the CEO and Founder of Hepion Pharmaceutical which is developing Rencofilstat, a drug in the category of cyclophilin inhibition to target cyclophilins a specific type of enzyme that is present in all humans. These cyclophilins perform a number of functions and are responsible to some extent for the...
Mar 9, 2022
Tom Isett is the CEO of iBio which is pioneering the next generation of biopharmaceuticals. Their goal is to reduce the cost, time, and risk of failure involved with drug discovery and development by using a plant-based recombinant protein manufacturing platform to create small and large batches of desired proteins. Tom...